Folic acid suppliers

Properties

Melting point:：

250 °C

alpha ：

20 º (c=1, 0.1N NaOH)

Boiling point:：

552.35°C (rough estimate)

bulk density：

110kg/m3

Density ：

1.4704 (rough estimate)

refractive index ：

1.6800 (estimate)

storage temp. ：

2-8°C

solubility ：

boiling water: soluble1%

pka：

pKa 2.5 (Uncertain)

form ：

Crystalline Powder

color ：

Yellow to orange

Odor：

Odorless

PH：

4.0-4.8 (25°C, 100g/L in H2O)

PH Range：

4

biological source：

synthetic (organic)

Water Solubility ：

1.6 mg/L (25 ºC)

Merck ：

14,4221

BRN ：

100781

BCS Class：

3

Stability:：

Stable. Incompatible with heavy metal ions, strong oxidizing agents, strong reducing agents. Solutions may be light and heat sensitive.

Cosmetics Ingredients Functions：

SKIN CONDITIONING

InChIKey：

OVBPIULPVIDEAO-LBPRGKRZSA-N

SMILES：

NC(N1)=NC(C2=C1N=CC(CNC3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)=O

LogP：

-0.990 (est)

CAS DataBase Reference：

59-30-3(CAS DataBase Reference)

NIST Chemistry Reference：

Folic acid(59-30-3)

EPA Substance Registry System：

L-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (59-30-3)

SecurityInformation

Symbol(GHS) ：

GHS07

Signal word ：

Warning

Hazard statements ：

H315-H319-H335

Precautionary statements ：

P261-P305+P351+P338

PPE：

Eyeshields, Gloves, type N95 (US)

Risk Statements ：

33-62-68

Safety Statements ：

24/25

WGK Germany ：

1

RTECS ：

LP5425000

F ：

8

TSCA ：

TSCA listed

HS Code ：

29362900

Storage Class：

11 - Combustible Solids

Hazardous Substances Data：

59-30-3(Hazardous Substances Data)

Toxicity：

A water soluble vitamin required in the diet of mammals. Sulfonamide drugs are selectively toxic to bacteria because they inhibit the incorporation of p-aminobenzoic acid into folic acid, a biosynthetic process in bacteria. Folic acid deficiency adversely affects prenatal development in humans. Dietary supplementation with folic acid dramatically reduces the incidence of neural tube defects in humans. Folic acid deficiency may also contribute to the causes of megaloblastic macrocytic anemia and a consequence of this is that this disease can be induced, as a side effect, when methotrexate, a folic acid antagonist, is used in cancer chemotherapy

REACH Registrations：

Active